Bio News

CellCentric Raises $220 Million to Develop Multiple Myeloma Drug

CellCentric has raised $220 million (approximately 319 billion won) in a Series D financing to develop inobrodib as a treatment for multiple myeloma. Inobrodib is an oral treatment for patients with relapsed multiple myeloma and may be particularly useful for patients who have re

2026-05-06

Symptoms Vary Widely Despite the Same Gene Deletion: ‘Multiple-Hit’ Model Identified

Differences in symptoms among patients with a chromosome 16p12.1 deletion appear to result from interactions with the broader genetic background beyond the eight genes. The research team identified this by differentiating patients’ induced pluripotent stem cells (iPSCs) into neur

2026-05-06

GSK to Acquire Chinese Obesity Drug Candidate for Up to $1.45 Billion, Targeting Abdominal Fat Reduction

GSK has entered into a technology transfer agreement with China’s Xilan Bio to acquire the obesity treatment candidate SA030, with a total value of up to $1 billion, including an upfront payment of $55 million. SA030, an oligonucleotide-based drug candidate, targets ALK7 and is i

2026-05-06

Bayer to acquire Perfuze for 3.5 trillion won, strengthening ophthalmology pipeline

Bayer will acquire Perfuze Therapeutics in a deal worth a total of 355 billion won, including an upfront payment of 43.5 billion won. Through the acquisition, Bayer secured PER-001, a Phase 2 ocular implant for the treatment of glaucoma and diabetic retinopathy. Bayer plans to st

2026-05-06

CellCentric Raises $220 Million for Multiple Myeloma Drug That Doubled Response Rate

CellCentric has raised $220 million to develop the multiple myeloma drug inobrodib, which doubled the response rate compared with existing treatments. The oral p300/CBP inhibitor is expected to enter a global phase 3 trial in the second half of this year. The company said the fun

2026-05-06

Recursion Increases Drug Candidate Discovery Efficiency by Up to 15-Fold With AI

Recursion Pharmaceuticals increased the efficiency of drug candidate discovery by up to 15-fold through its AI platform, while the oncology candidate REC-1245 demonstrated safety in an early clinical trial without dose-limiting toxicity. REC-1245 is an RBM39 protein degrader that

2026-05-06

“Even Without a Single-Formulation Product, Launch Planned for 2027” … Novo Maintains CagriSema Plans

Novo Nordisk has discontinued development of a single-formulation version of the GLP-1/amylin combination drug CagriSema but is maintaining its plan for a launch in early 2027. The treatment, which combines semaglutide and cagrilintide, is expected to be supplied through a dual-c

2026-05-06

India to invest $330 billion in API park to reduce dependence on China

India will invest a total of 330 billion won to develop the 1,400-acre Haroli active pharmaceutical ingredient (API) park in an effort to reduce its dependence on APIs from China. The project aims to lower entry barriers for individual manufacturers and reduce production costs by

2026-05-06

Ramky to Invest 300 Billion Rupees and Operate 1,000-Hectare Life Sciences City for 95 Years

India’s Ramky Infrastructure will invest 300 billion rupees to develop a 1,000-hectare life sciences city. The project will be carried out through a public-private partnership (PPP), and Ramky has secured operating rights for a total of 95 years, including a five-year constructio

2026-05-06

Study Identifies Cause of Antibiotic Resistance Through Analysis of More Than 500 Metabolites in Single Cells

Using a new single-cell metabolomics analysis platform called “SinBactM,” researchers analyzed more than 500 metabolic features in individual bacterial cells and discovered a rare resistance-like state that causes antibiotic resistance. The system combines microextraction and mas

2026-05-06